Bristol-Myers Squibb
Bristol-Myers to acquire hepatitis C oral drug developer Inhibitex for $2.5 bn
09 Jan 2012
Bristol-Myers Squibb over the weekend said that it will buy Inhibitex Inc, for about $2.5 billion in cash in order to expand its broad hepatitis C portfolio
Bristol-Myers to divest Mead Johnson for $7.69 billion
16 Nov 2009
Leading maker of children's nutritional products, the over 100-year Mead Johnson had 2008 sales of nearly $2.6 billion
Sigma acquires Bristol-Myers Sqibb’s brands
07 Sep 2009
